Log In
Print this Print this

Subcutaneous Actemra, Subcutaneous RoActemra, tocilizumab

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionSubcutaneous formulation of a humanized mAb against IL-6 receptor
Molecular Target Interleukin-6 (IL-6) receptor (CD126)
Mechanism of ActionInterleukin-6 (IL-6) receptor (CD126) inhibitor; Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today